BIT
0.002
100%
ABR
0.002
-33.3%
VBC
0.235
27%
M2M
0.005
-28.6%
EDE
0.065
20.4%
BNL
0.003
-25%
IPD
0.006
20%
CLA
0.003
-25%
D3E
0.29
18.4%
MQR
0.003
-25%
VMT
0.088
17.3%
REZ
0.007
-22.2%
BEZ
0.075
17.2%
GLL
0.004
-20%
FCT
0.007
16.7%
R8R
0.08
-20%
INF
0.007
16.7%
CHW
0.75
-17.6%
MDI
0.014
16.7%
BUR
0.03
-16.7%
RAN
0.1
16.3%
RAD
0.005
-16.7%
GT1
0.015
15.4%
RPM
0.011
-15.4%
LML
0.015
15.4%
SNG
0.033
-15.4%
EVE
0.016
14.3%
VHL
0.011
-15.4%
LSR
0.008
14.3%
SHN
0.028
-15.2%
TMS
0.008
14.3%
4DS
0.006
-14.3%
AIM
0.245
14%
AEV
0.006
-14.3%
ROC
0.245
14%
WBT
3.42
-13%
LGI
2.2
13.1%
VSR
0.02
-13%
1AI
0.009
12.5%
A8G
0.17
-12.8%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Arovella Therapeutics (ASX:ALA): A novel cell therapy treatment for cancers and tumours

Ahead of appearing at the Spark+ Australian Equities Day in Singapore, Arovella’s (ASX:ALA) CEO & Managing Director Dr Michael Baker speaks with The Stock Network’s Lel Smits about:

🩸 The current lead product coming out of Arovella Therapeutics’ cell therapy platform – ALA-101 – iNKT cells create receptors that target antigens
🩸 How ALA-101 targets cancers and tumours
🩸 Timing of Phase 1 trials for ALA-101

Watch the full interview ⚡️ https://youtu.be/Hb_HZmKYCNA
Register to attend Australian Equities Day: https://www.eventbrite.sg/e/spark-plus-australian-equities-day-tickets-939180011697